Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Global X Robo Global Robotics & Automation ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.42 (market cap $8.04B), while Global X Robo Global Robotics & Automation ETF trades at $81.06. The key difference: Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | ROBO | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $339.75 | $90.34 |
52-Week Low | $241.71 | $60.15 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
ROBO, the ROBO Global Robotics and Automation Index ETF, trades at $80.56, down 2.89% over 24 hours amid a bearish technical signal. Key support lies at $79, with resistance at $82. Recent news highlights its diversified AI-driven portfolio and a rebalance toward AI infrastructure, though valuation metrics are not provided in the snapshot. The ETF's performance reflects sector-specific momentum and exposure to cyclical markets like automotive.
Outlook remains mixed; the ETF offers growth exposure to robotics and AI themes, but bearish technical indicators and cyclical risks warrant caution. Investment appeal hinges on sustained AI adoption, while risks include market volatility and competitive pressures in the technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
